ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,238,163 | +9.0% | 259,135 | +41.1% | 1.68% | +27.2% |
| Q2 2023 | $8,473,896 | +15.0% | 183,696 | 0.0% | 1.32% | +7.5% |
| Q1 2023 | $7,366,210 | -13.4% | 183,696 | 0.0% | 1.23% | -32.6% |
| Q4 2022 | $8,510,636 | +18.3% | 183,696 | +5.8% | 1.83% | +83.1% |
| Q3 2022 | $7,193,000 | +46.4% | 173,696 | +51.0% | 1.00% | +146.4% |
| Q4 2019 | $4,912,000 | -4.4% | 115,000 | +9.5% | 0.40% | -69.6% |
| Q2 2016 | $5,136,000 | +73.7% | 105,000 | +242.0% | 1.33% | +253.6% |
| Q3 2015 | $2,957,000 | -39.5% | 30,700 | -35.6% | 0.38% | -21.1% |
| Q2 2015 | $4,884,000 | – | 47,700 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |